These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32401726)

  • 1. Doxycycline, an Antibiotic or an Anti-Inflammatory Agent? The Most Common Uses in Dermatology.
    Navarro-Triviño FJ; Pérez-López I; Ruiz-Villaverde R
    Actas Dermosifiliogr (Engl Ed); 2020 Sep; 111(7):561-566. PubMed ID: 32401726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-antibiotic properties of tetracyclines and their clinical application in dermatology.
    Perret LJ; Tait CP
    Australas J Dermatol; 2014 May; 55(2):111-8. PubMed ID: 23808657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetracyclines: nonantibiotic properties and their clinical implications.
    Sapadin AN; Fleischmajer R
    J Am Acad Dermatol; 2006 Feb; 54(2):258-65. PubMed ID: 16443056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical applications of non-antimicrobial tetracyclines in dermatology.
    Monk E; Shalita A; Siegel DM
    Pharmacol Res; 2011 Feb; 63(2):130-45. PubMed ID: 20937386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial.
    Chalmers JR; Wojnarowska F; Kirtschig G; Mason J; Childs M; Whitham D; Harman K; Chapman A; Walton S; Schmidt E; Godec TR; Nunn AJ; Williams HC
    Health Technol Assess; 2017 Mar; 21(10):1-90. PubMed ID: 28406394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxycycline, a Well-Tolerated, Economic, and Effective Alternative for the First-Line Treatment of Bullous Pemphigoid.
    Morgado-Carrasco D; Riquelme-Mac Loughlin C; Fustà-Novell X; Iranzo P
    Actas Dermosifiliogr (Engl Ed); 2018; 109(6):549-550. PubMed ID: 29175174
    [No Abstract]   [Full Text] [Related]  

  • 7. Second-generation tetracyclines, a dermatologic overview: clinical uses and pharmacology.
    Maibach H
    Cutis; 1991 Nov; 48(5):411-7. PubMed ID: 1764965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxycycline as an anti-inflammatory agent: updates in dermatology.
    Henehan M; Montuno M; De Benedetto A
    J Eur Acad Dermatol Venereol; 2017 Nov; 31(11):1800-1808. PubMed ID: 28516469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Doxycycline or how to create new with the old?].
    Shehwaro N; Langlois AL; Gueutin V; Gauthier M; Casenave M; Izzedine H
    Therapie; 2014; 69(2):129-41. PubMed ID: 24926631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetracycline repurposing in neurodegeneration: focus on Parkinson's disease.
    Bortolanza M; Nascimento GC; Socias SB; Ploper D; Chehín RN; Raisman-Vozari R; Del-Bel E
    J Neural Transm (Vienna); 2018 Oct; 125(10):1403-1415. PubMed ID: 30109452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-inflammatory effects of tetracyclines.
    Weinberg JM
    Cutis; 2005 Apr; 75(4 Suppl):6-11. PubMed ID: 15916224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sarecycline Demonstrates Clinical Effectiveness against Staphylococcal Infections and Inflammatory Dermatoses: Evidence for Improving Antibiotic Stewardship in Dermatology.
    Grada A; Ghannoum MA; Bunick CG
    Antibiotics (Basel); 2022 May; 11(6):. PubMed ID: 35740129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action.
    Griffin MO; Ceballos G; Villarreal FJ
    Pharmacol Res; 2011 Feb; 63(2):102-7. PubMed ID: 20951211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioral dermatitis and rosacea-like dermatitis: clinical features and treatment.
    Urabe H; Kōda H
    Dermatologica; 1976; 152 Suppl 1():155-60. PubMed ID: 133838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetracyclines-An Important Therapeutic Tool for Dermatologists.
    Orylska-Ratynska M; Placek W; Owczarczyk-Saczonek A
    Int J Environ Res Public Health; 2022 Jun; 19(12):. PubMed ID: 35742496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New uses for older antibiotics. The 'rediscovery' of four beneficial and cost-effective antimicrobials.
    Cunha BA
    Postgrad Med; 1997 Apr; 101(4):68-70, 73-4, 79-80 passim. PubMed ID: 9126205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-antibacterial tetracyclines modulate mediators of periodontitis and atherosclerotic cardiovascular disease: a mechanistic link between local and systemic inflammation.
    Gu Y; Lee HM; Sorsa T; Salminen A; Ryan ME; Slepian MJ; Golub LM
    Pharmacol Res; 2011 Dec; 64(6):573-9. PubMed ID: 21771657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-inflammatory activity of tetracyclines.
    Webster G; Del Rosso JQ
    Dermatol Clin; 2007 Apr; 25(2):133-5, v. PubMed ID: 17430750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use and safety of doxycycline hyclate and other second-generation tetracyclines.
    Sloan B; Scheinfeld N
    Expert Opin Drug Saf; 2008 Sep; 7(5):571-7. PubMed ID: 18759709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subantimicrobial-dose doxycycline monohydrate in dermatology.
    Wollina U
    Wien Med Wochenschr; 2015 Dec; 165(23-24):499-503. PubMed ID: 26564206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.